GI Innovation

GI Innovation, founded in 2017, is a drug developer built around dual fusion protein and bispecific antibody discovery, using its proprietary 'GI-SMART™' platform as its core technological differentiator.

Its main pipeline includes the immuno-oncology candidates GI-101/GI-101A and GI-102, the allergy treatment candidate GI-301, the metabolic-immuno-oncology candidate GI-108, and the pulmonary arterial hypertension candidate GI-214.

GI-301 was out-licensed to Yuhan Corporation in 2020 for rights excluding Japan, valued at approximately KRW 1.4 trillion, with a separate license to Maruho of Japan signed in October 2023; the asset is now in domestic Phase 2 trials under Yuhan under the name Resigersept.

GI-101's rights for China, Hong Kong, Macau, and Taiwan were licensed to China's CStone/Simcere in 2019 for roughly KRW 900 billion to KRW 1.146 trillion, while GI Innovation retains rights outside that territory.

GI-101A and GI-102 are being developed around collaborations with major global pharmaceutical companies, including a joint clinical agreement with MSD for Keytruda combination trials (signed July 2020, renewed August 2024) and a collaboration with Johnson & Johnson combining GI-102 with the bispecific pasritamig.

These co-development arrangements typically involve the global partner supplying its own drug free of charge, allowing GI Innovation to validate pipeline value without bearing the full cost of large-scale trials.

Revenue is largely derived from upfront payments and milestones tied to licensing agreements, reflecting the typical structure of an early-stage biotech that has not yet generated commercial product sales.

Annual revenue in 2025 rose sharply to KRW 5.84 billion from just KRW 24.28 million in 2024, though the absolute level remains minimal.

Operating loss narrowed to KRW 40.65 billion in 2025 from KRW 48.26 billion in 2024, and net loss attributable to owners also declined to KRW 35.13 billion from KRW 58.78 billion, showing some moderation in loss size.

Still, operating losses ranged between roughly KRW 50 billion and KRW 68 billion in each of 2022 through 2024, reflecting a structural deficit tied to heavy R&D spending.

On a quarterly basis, operating losses eased from KRW 10.89 billion in 2025Q2 to KRW 10.74 billion in 2025Q3 and KRW 7.19 billion in 2025Q4, before widening again to KRW 12.35 billion in 2026Q1 and KRW 14.38 billion in 2026Q2.

Revenue also reverted to zero in 2026Q1 and 2026Q2 after KRW 5.5 billion was recognized in 2025Q4, illustrating a discontinuous revenue pattern tied to specific contract or milestone timing rather than recurring sales.

Cumulative net loss attributable to owners over the trailing four quarters (2025Q3-2026Q2) reached KRW 39.14 billion, underscoring that large-scale losses have persisted on an annualized basis as well.

Operating cash flow improved to negative KRW 32.30 billion in 2025 from negative KRW 43.43 billion in 2024, though cash outflows remain substantial.

Total equity rose sharply to KRW 116.49 billion in 2025 from KRW 29.05 billion in 2024, a change largely attributable to a rights offering of roughly KRW 110 billion completed in March 2025.

In the immuno-oncology space, IL-2-based fusion protein strategies combined with PD-1/PD-L1 pathways are being competitively pursued by numerous global biotechs, with demonstrated clinical differentiation and safety profiles seen as key variables for successful licensing.

Large global pharmaceutical companies have reportedly become more selective, favoring assets with validated data, which raises the bar for early-stage pipelines to convert into actual deals.

Many Korean technology-listed biotech companies share a similar structure in which corporate value hinges heavily on licensing deals during a prolonged pre-revenue period, and GI Innovation shares this industry characteristic.

The company has a track record of three prior global licensing deals - GI-101 to China's Simcere and GI-301 to Yuhan and Maruho - which market observers view as a differentiating factor relative to domestic peers.

However, the absence of a major follow-on licensing deal since the 2019 China transaction has been repeatedly flagged as a persistent weakness.

Collaborations with MSD and Johnson & Johnson can be read as signals that global pharmaceutical companies selected the domestic biotech's assets as part of their own pipeline strategies, though whether these partnerships ultimately convert into formal licensing contracts remains to be confirmed.

The company has positioned 2026 as a year focused on achieving global licensing outcomes centered on GI-101A.

Phase 1 data for both monotherapy and Keytruda combination arms of GI-101A were disclosed via an oral presentation at ASCO 2026, and around the time of the May presentation a company representative stated that "due diligence for GI-101A has been completed and detailed contract discussions are now underway." The company indicated that additional follow-on clinical data for GI-101A - including a subcutaneous formulation, ADC combination, and Keytruda combination - would be disclosed later within the year.

For GI-102, a Phase 1b/2 combination trial with Johnson & Johnson's bispecific pasritamig in metastatic castration-resistant prostate cancer received FDA IND approval in April 2026, with dosing beginning in May, positioning initial data to potentially become available within the year.

A Phase 2 trial combining GI-102 with Keytruda as a direct comparison for first-line melanoma treatment is also underway, with initial results reportedly expected in the first quarter of 2027 (Yakup Gongron, April 2026).

The company reported holding multiple meetings with global venture capital investors at an April industry forum, noting interest in newer pipeline assets such as GI-102 where full rights remain with the company.

As a technology-listed company, the revenue requirement exemption runs through 2027, making progress toward tangible licensing outcomes or a broader revenue base before that deadline an important point to monitor.